On 12 February 2021, the MS Network of Care and CCSVI Australia jointly provided the Australian Government’s Health Technology Reference Group (an advisory body for all Australian and New Zealand Health Ministers) with a ten year evaluation of what is being learnt regarding the role of Angioplasty in treating CCSVI conditions in MS. In doing this it sought advice about the role of the Health Technology Group in guiding all Ministers (and medical professionals) concerning the benefits for Venoplasty for those living with an MS diagnosis.

What makes this submission different is that it incorporates and respects the importance of long-term patient centred qualitative benchmarks in the evaluation process – something too frequently marginalised or ignored by some decision makers. For those so inclined, your State/Territory Health Ministers/Elected Members might also appreciate you drawing this to their attention.

The link is: http://www.msnetwork.org/evidence/health-ministers-feedback.html